Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juni 2026 05:00 ET | Quelle: Resalis Therapeutics SRL

Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity

Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide...
22. Januar 2026 05:00 ET | Quelle: Resalis Therapeutics SRL

Resalis Therapeutics Appoints Sandor Batkai as Medical Director

Torino, Italy, January 22 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment of Sandor Batkai, MD, PhD, as Medical Director. Dr....
07. Oktober 2025 05:00 ET | Quelle: Resalis Therapeutics SRL

Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class...